Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy

Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy

Source: 
BioSpace
snippet: 

Less than a year ago, Bristol Myers Squibb’s Yervoy received approval for previously untreated non-small cell lung cancer in a combination of Opdivo and Yervoy. Today, Merck released first-time data from the Phase III KEYNOTE-598 trial of Keytruda in combination with Yervoy (ipilimumab) compared to Keytruda alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) without EGFR or ALK genomic tumor aberrations and whose tumors express PD-L1.